Johnson & Johnson vs Merck & Company, Inc.
A head-to-head of Johnson & Johnson (JNJ) and Merck & Company, Inc. (MRK) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | JNJ | MRK |
|---|---|---|
| Market Cap | $555.94B | $289.52B |
| P/E (TTM) | 25.81 | 32.31 |
| Forward P/E | 17.72 | 12.41 |
| P/S | 5.77 | 4.40 |
| P/B | 8.58 | 8.93 |
| EV/EBITDA | 17.48 | 17.18 |
| Dividend Yield | 1.80% | 2.01% |
| Profit Margin | 21.83% | 13.59% |
| Gross Margin | 67.88% | 74.80% |
| Operating Margin | 27.17% | 34.01% |
| Revenue Growth (YoY) | +9.91% | +4.87% |
| FCF Yield | 3.13% | 4.88% |
| Debt / Equity | 67.73 | 106.94 |
| Current Ratio | 1.03 | 1.30 |
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.